WA SB5204

University of Washington required to conduct a three-year prospective, randomized cohort study on ibogaine-assisted therapy for adults with opioid use disorder

Study will compare outcomes of ibogaine treatment at licensed clinics in Mexico (with follow-up therapeutic support) against standard U.S. treatments including medication-assisted treatment and psychotherapy

Measured outcomes must include treatment engagement, reduction in opioid use, mortality, functional status, craving, motivation to change, and self-efficacy

Ibogaine is a naturally occurring psychoactive substance from the Tabernanthe iboga plant, currently classified as Schedule I in the U.S., limiting domestic research opportunities

Washington has previously funded research on ibogaine cardiac safety, finding minimal risk when administered in medical settings